Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Nolan

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Bioorganic & Medicinal Chemistry Letters|April 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK propertiesMaria V Sergeeva, Yuefen Zhou, Darian M Bartkowski, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Stephen E Webber, Martin T Tran, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2009
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Chinh V Tran, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
PNAS Nexus|February 12, 2024
Multipotent bone marrow cell-seeded polymeric composites drive long-term, definitive urinary bladder tissue regenerationMatthew I Bury, Natalie J Fuller, Xinlong Wang, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2008
5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Chinh V Tran, Lian-Sheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymeraseFrank Ruebsam, Douglas E Murphy, Chinh V Tran, et al.
Cancer Discovery|April 19, 2026
Therapy-related mutational signatures in subsequent neoplasms among survivors of childhood cancerSamuel W Brady, Michael A Arnold, Mingjuan Wang, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Bioorganic & Medicinal Chemistry Letters|April 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK propertiesMaria V Sergeeva, Yuefen Zhou, Darian M Bartkowski, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Stephen E Webber, Martin T Tran, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2009
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Chinh V Tran, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
PNAS Nexus|February 12, 2024
Multipotent bone marrow cell-seeded polymeric composites drive long-term, definitive urinary bladder tissue regenerationMatthew I Bury, Natalie J Fuller, Xinlong Wang, et al.
Bioorganic & Medicinal Chemistry Letters|December 5, 2008
5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseFrank Ruebsam, Chinh V Tran, Lian-Sheng Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymeraseFrank Ruebsam, Douglas E Murphy, Chinh V Tran, et al.
Cancer Discovery|April 19, 2026
Therapy-related mutational signatures in subsequent neoplasms among survivors of childhood cancerSamuel W Brady, Michael A Arnold, Mingjuan Wang, et al.
Pageof 18